Sanofi to buy Blueprint Medicines for over $9 billion
By 
Phillip Broadwith2025-06-04T14:42:00
Blueprint has one approved drug and enhances Sanofi’s immunology portfolio
As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint Medicines in a deal worth $9.1 billion (£6.7 billion) in cash, with an additional $400 million on offer in performance milestone payments.